secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001818382-24-000005
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Priority Review to Humacyte's HAV BLA; PDUFA date August 10, 2024
----------------------------------------------------------------------------

- BLA for Human Acellular Vessel in urgent arterial repair after extremity vascular trauma accepted with Priority Review.
- PDUFA action date set for August 10, 2024; six-month review vs. standard ten months.
- Supporting data from Phase 2/3 V005 trial and real-world use in Ukraine wartime injuries.
- HAV showed higher patency, lower amputation and infection rates versus historic synthetic graft benchmarks.
- Priority Review aligns with prior RMAT designation and DoD priority designation under Public Law 115-92.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000005/0001818382-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000005/huma-20240209.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer